Resveratrol as an immune checkpoint inhibitor to enhance the efficacy of breast cancer immunotherapy
محل انتشار: مجله علوم پایه پزشکی ایران، دوره: 29، شماره: 11
سال انتشار: 1405
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 19
فایل این مقاله در 17 صفحه با فرمت PDF قابل دریافت می باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_IJBMS-29-11_002
تاریخ نمایه سازی: 22 آبان 1405
چکیده مقاله:
A major goal in cancer treatment is to convert “cold” tumors into “hot” ones by altering the tumor microenvironment (TME). Breast cancer is often a cold tumor and is resistant to immunotherapy. Resveratrol is a polyphenolic compound found in grapes, with antioxidant, anti-inflammatory, and potential cardioprotective and anti-aging properties. Resveratrol promotes the conversion of immunologically cold breast tumors into hot tumors, thereby increasing the efficacy of immunotherapy. This article reviews the potential of resveratrol to convert immunologically “cold” breast tumors into “hot” tumors by modulating the TME and enhancing the efficacy of immunotherapy. A comprehensive literature search was conducted in PubMed, Scopus, Web of Science, and Google Scholar to identify English-language articles investigating the effects of resveratrol on immune checkpoints in breast cancer. The results showed that resveratrol suppresses key cancer-promoting pathways (PI۳K/Akt/mTOR, MAPK/ERK, STAT/NF-κB, and Wnt/β-catenin) and modulates the immune system. It boosts anti-tumor immunity by activating immunostimulatory cells (such as M۱-TAMs, NKs, and CTLs) while simultaneously inhibiting immunosuppressive cells (such as Tregs and MDSCs). It also acts as a natural immune checkpoint inhibitor by targeting the PD-۱/PD-L۱ pathway. Resveratrol prevents T-cell exhaustion in “cold” tumors and reduces PD-L۱ expression in “hot” tumors, thereby enhancing cytotoxic T cells’ ability to attack cancer. However, its effectiveness is limited by poor bioavailability and differences in the biological activity of its metabolites. Future clinical studies are needed to confirm these results and determine optimal therapeutic protocols for resveratrol-mediated breast cancer immunotherapy.
کلیدواژه ها:
نویسندگان
- -
Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
- -
Lombardi Compr ehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, DC, United States
- -
Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
- -
Department of Pharmacognosy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
مراجع و منابع این مقاله:
لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :